

# Patient - PACT

## New Clinical Trial and Research



Trial title	A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
Trial synopsis	This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) compared with placebo in participants with idiopathic pulmonary fibrosis (IPF).
Investigational medicinal product	PRM-151 or placebo
Disease target	Idiopathic pulmonary fibrosis
Sponsor	F. Hoffmann-La Roche Ltd
Duration	Start (ANZ): April-2021 to March-2023 Participants will receive intravenous (IV) infusions of PRM-151 or placebo over 50-70 minutes on Days 1, 3 and 5, then followed by infusions every 4 weeks (Q4W) to Week 48.
Trial Status	Recruitment paused due to drug supply limitations – due to re-open June 2022
Lead site(s) in Australia	Lung Research Queensland (private sites) and Princess Alexandra Hospital (public sites)
Lead site(s) in New Zealand	University of Otago, Christchurch
Additional sites	<p>AUSTRALIA</p> <ul style="list-style-type: none"> <li>• WA Fiona Stanley Hospital, Michael Musk</li> <li>• VIC Monash Medical Centre Clayton, Xun Li</li> <li>• NSW Royal Prince Alfred Hospital, Tamera Corte</li> <li>• QLD Lung Research Queensland, Dan Chambers</li> <li>• VIC The Alfred Hospital, Ian Glaspole</li> <li>• QLD Princess Alexandra Hospital, Gregory Keir</li> <li>• Cairns Hospital QLD PI: Dr James Brown</li> </ul> <p>NEW ZEALAND</p> <ul style="list-style-type: none"> <li>• Tauranga Hospital, Suzanne Poole</li> <li>• NZ Respiratory and Sleep Institute, Andrew Veale</li> <li>• Auckland City Hospital, Margaret Wilsher</li> <li>• Waikato Hospital, Catherina Chang</li> <li>• Research and Enterprise University of Otago, Lutz Beckert</li> </ul>
Contact	pactcoordinator@cre-pf.org.au